AbCellera Biologics (ABCL) Non-Current Deferred Tax Liability (2020 - 2025)

AbCellera Biologics (ABCL) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $9.1 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability fell 9.32% year-over-year to $9.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.1 million (down 9.32% YoY) and the FY2025 annual result came in at $9.1 million, down 9.32% from the prior year.
• Non-Current Deferred Tax Liability eased to $9.1 million in Q4 2025, from $9.7 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $77.2 million in Q4 2023 to a low of $9.1 million in Q4 2025.
• A 5-year average of $27.8 million and a median of $31.7 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability jumped 132.61% — and 2024, when it slumped 86.98%.
• Tracing ABCL's Non-Current Deferred Tax Liability over 5 years: stood at $37.4 million in 2021, then retreated by 11.22% to $33.2 million in 2022, then jumped by 132.61% to $77.2 million in 2023, then tumbled by 86.98% to $10.1 million in 2024, then dropped by 9.32% to $9.1 million in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $9.1 million (Q4 2025), $9.7 million (Q3 2025), and $10.1 million (Q2 2025), per Business Quant data.